Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
Arcutis Biotherapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Arcutis Biotherapeutics's price to book ratio was 16.2× on Nov 11, 2026, against 23.3× a year earlier. Over the last 5 years it ranged from 1.7× to 23.3×, with a median of 7.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 16.2× | −5.9 |
| 2025 | Dec 31, 2025 | 22.1× | +11.7 |
| 2024 | Dec 31, 2024 | 10.4× | +6.1 |
| 2023 | Dec 29, 2023 | 4.3× | +0.9 |
| 2022 | Dec 30, 2022 | 3.3× | +0.5 |
| 2021 | Dec 31, 2021 | 2.9× | −3.3 |
| 2020 | Dec 31, 2020 | 6.1× | – |
See a number that looks wrong?